Pulmonology Department, Hospital del Mar-IMIM. CEXS, Universitat Pompeu Fabra, CIBERES, ISCiii, Barcelona, Spain.
Pneumology Department, Respiratory Institute (ICR), Hospital Clinic of Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), SGR 911- Ciber de Enfermedades Respiratorias (CIBERES), ICREA Academia, Barcelona, Spain.
Respir Res. 2018 Jun 15;19(1):119. doi: 10.1186/s12931-018-0820-1.
Antimicrobial treatment for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) remains controversial. In some cases AECOPD are caused by microorganisms that are resistant to treatments recommended by guidelines. Our aims were: 1) identify the risk factors associated with infection by microorganisms resistant to conventional treatment (MRCT), 2) Compare the clinical characteristics and outcomes of patients with AECOPD resulting from MRCT against those with AECOPD from other causes.
We prospective analysed a cohort of patients admitted with severe AECOPD (2009 to 2015) who were assigned to three groups: patients with MRCT (those patients with germs resistant to antibiotics recommended in guidelines), patients with microorganisms sensitive to conventional antimicrobial treatment (MSCT), and patients with negative microbiology results who had not previously received antibiotics. Multinomial logistic regression analyses were used to examine the associations between microbial aetiology groups and risk factors. The association between LOS and risk factors was also tested in simple and multiple analyses, and similar inclusion criteria were applied for the linear regression analysis.
Of the 451 patients admitted, 195 patients (43%) were included. Respiratory cultures were positive in 86(44%) and negative in 109(56%). MRCT were isolated in 34 cases (40%) and MSCT in 52 (60%). Patients with MRCT had more AECOPD in the previous year, received more antibiotic treatment in the previous three months, had more severe disease, higher dyspnoea and a positive respiratory culture in the previous year (mainly for Pseudomonas aeruginosa). The following conditions were independent factors for MRCT isolation: non-current smoker (odds ratio [OR] 4.19 [95% confidence interval [CI] 1.29-13.67], p = 0.017), ≥ 2 AECOPD or ≥ 1 admission for AECOPD in the previous year (OR 4.13 [95% CI 1.52-11.17], p = 0.005), C-reactive protein < 5 mg/dL; (OR 3.58 [95% CI 1.41-9.07], p = 0.007). Mortality rates were comparable at 30-days, one year and 3 years; however, patients in the MRCT group had longer hospital stays.
In conclusion, there are risk factors for resistant germs in AECOPD; however, the presence of these germs does not increase mortality. Patients with isolation of MRCT had longer length of stay.
慢性阻塞性肺疾病(COPD)急性加重期(AECOPD)的抗菌治疗仍存在争议。在某些情况下,AECOPD 是由对抗生素治疗指南推荐的治疗方法耐药的微生物引起的。我们的目的是:1)确定与常规治疗耐药的微生物(MRCT)相关的感染风险因素,2)比较因 MRCT 导致的 AECOPD 患者与其他原因导致的 AECOPD 患者的临床特征和结局。
我们前瞻性分析了一组因重度 AECOPD 入院的患者(2009 年至 2015 年),将这些患者分为三组:MRCT 患者(对指南推荐的抗生素耐药的病菌)、MSCT 患者(对常规抗菌治疗敏感的微生物)和未接受过抗生素治疗且微生物学检查结果阴性的患者。使用多项逻辑回归分析来检查微生物病因组与风险因素之间的关联。还分别进行了 LOS 与风险因素的简单和多元分析,并应用了相似的纳入标准进行线性回归分析。
在 451 名入院患者中,有 195 名患者(43%)入选。86 例(44%)患者的呼吸道培养阳性,109 例(56%)患者的呼吸道培养阴性。MRCT 分离出 34 例(40%),MSCT 分离出 52 例(60%)。MRCT 组患者 AECOPD 发作次数更多、过去三个月内接受的抗生素治疗更多、病情更严重、呼吸困难程度更高、且去年呼吸道培养阳性(主要为铜绿假单胞菌)。以下条件是 MRCT 分离的独立因素:非当前吸烟者(比值比 [OR] 4.19 [95%置信区间 [CI] 1.29-13.67],p=0.017)、过去一年中≥2 次 AECOPD 或≥1 次 AECOPD 住院(OR 4.13 [95% CI 1.52-11.17],p=0.005)、C 反应蛋白 <5mg/dL(OR 3.58 [95% CI 1.41-9.07],p=0.007)。30 天、1 年和 3 年的死亡率相当,但 MRCT 组患者的住院时间更长。
总之,AECOPD 中有对抗生素耐药的微生物的危险因素,但这些微生物的存在并不增加死亡率。MRCT 分离的患者住院时间更长。